John Vu, MD
Medical Oncology · Jacksonville, FLNPI 1497956072
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,597 of the $8,710 with a category attached, or 87.2%. 12 manufacturers reported payments, led by Amgen at 39.1% of the total. Reporting peaked in 2023 at $3,171 and has fallen 86.2% since, to $437 in 2025. That places this record below the midpoint for medical oncology clinicians in FL, where the typical reported total is $8,890.
Across 18 payments — averaging $483.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- AstraZeneca$3K
- E.r. Squibb & Sons, L.L.C.$2K
- Caris MPI, Inc.$125
- Immunocore Limited$116
- Boehringer Ingelheim$110
- plus $169 from 6 others
Across 40 payments — averaging $18,443 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$376K
- E.r. Squibb & Sons, L.L.C.$120K
- Novartis$80K
- Pfizer$65K
- Janssen Research & Development, LLC$57K
- Amgen$25K
- plus $15K from 2 others
What the payments were for
- Consulting fees$7,59787%
- Food & beverage$1,10213%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 4 | $3,403 |
| AstraZeneca | 4 | $3,078 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,710 |
| Caris MPI, Inc. | 1 | $125 |
| Immunocore Limited | 1 | $116 |
| Boehringer Ingelheim | 1 | $110 |
| G1 Therapeutics, Inc. | 1 | $84 |
| EMD Serono, Inc. | 1 | $20 |
| Bristol Myers Squibb | 1 | $19 |
| Novocure Inc. | 1 | $19 |
| Genentech USA, Inc. | 1 | $15 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$2,931
- LUMAKRAS$202
- MI CANCER SEEK$125
- KIMMTRAK$116
How this compares
$8,710 in reported general payments places this provider in the 45th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 70 | $1,233,870 |
| LenvimaLenvatinib Mesylate | 12 | $291,526 |
| InlytaAxitinib | 12 | $231,599 |
| SorafenibSorafenib Tosylate | 13 | $49,030 |
| EliquisApixaban | 61 | $42,538 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $8,900 |
| OxycontinOxycodone Hcl | 11 | $8,424 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 45 | $1,597 |
| Ondansetron Hcl | 88 | $1,451 |
| Prochlorperazine Maleate | 92 | $1,352 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 30 | $1,286 |
| Oxycodone Hcl | 33 | $468 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 45 | $431 |
| Gabapentin | 50 | $418 |
| Dexamethasone | 15 | $376 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $3,078 | $1,233,87070 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 507 medical oncology providers in Florida.
Other medical oncology in Jacksonville
- Neil LoveMiami$5.6M
- Mahdi TahaBoca Raton$1.7M
- Raji ShameemOrlando$1.3M
- Mohammad JahanzebBoca Raton$1.3M
- Michel VelezOrlando$927K
- Yuanbin ChenOrlando$810K
- Reshma MahtaniPlantation$608K
- Rebecca MorooseOrlando$543K
- Yasser KhaledOrlando$444K
- Judah FriedmanPalm Beach Gardens$416K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.